MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

MDT

100.81

+0.69%↑

A

139.19

+2.17%↑

VEEV

224.79

+2.19%↑

HQY

85.18

+0.72%↑

NEOG

9.99

+5.83%↑

Search

TransMedics Group Inc

Abierto

SectorSalud

132.92 -2.86

Resumen

Variación precio

24h

Actual

Mínimo

131.5

Máximo

137.81

Métricas clave

By Trading Economics

Ingresos

-11M

24M

Ventas

-14M

144M

P/B

Media del Sector

56.445

89.037

Margen de beneficio

16.909

Empleados

728

EBITDA

-13M

33M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+6.7% upside

Dividendos

By Dow Jones

Próximas Ganancias

26 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

384M

4.9B

Apertura anterior

135.78

Cierre anterior

132.92

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

177 / 360 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

TransMedics Group Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2025, 19:15 UTC

Principales Movimientos del Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Comparación entre iguales

Cambio de precio

TransMedics Group Inc Esperado

Precio Objetivo

By TipRanks

6.7% repunte

Estimación a 12 meses

Media 151.44 USD  6.7%

Máximo 170 USD

Mínimo 135 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para TransMedics Group Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

9

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

92.43 / 94.18Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

177 / 360 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat